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Silnln'lary 
The availability of antitumor cytotoxic T lymphocytes which can be generated from either peripheral 
blood lymphocytes after stimulation in vitro or tumor infiltrating lymphocytes (TIL) has made 
it possible  to identify a number of melanoma antigens presented by major histocompatibility 
complex class I molecules. The present and previous studies indicated that TIL586 recognized 
an antigen expressed on most melanoma and normal melanocytes in the context of the HLA-A31 
molecule. We report here the cloning of a cDNA that directs the expression of the shared melanoma 
antigen recognized by this TIL. The DNA sequence analysis revealed that the cDNA was almost 
identical to the gene encoding tyrosinase-related protein 1 or glycoprotein gp75 which was originally 
identified by serum antibodies in a patient with melanoma. The gene was found to be expressed 
only in melanoma, normal melanocyte cell lines, and retina, but not in other normal tissues 
tested. The gp75 antigen presented by HLA-A31 may therefore constitute a useful immune target 
for specific treatment of patients with melanoma, since both antibody- and T cell-mediated immune 
responses  can be generated against this antigen. 
T 
he adoptive transfer of T cells can mediate tumor regres- 
sion in patients with metastatic melanoma (1, 2). CTL 
which recognize melanoma cells in an MHC class I-restricted 
manner can be generated from either PBL or tumor-infiltrating 
lymphocytes (TIL) of patients with melanoma (3-7).  The 
availability  of these CTL has made it possible  to isolate a 
number of tumor-associated antigens recognized by T cells 
(8).  Identification of the antigens recognized by T  cells on 
tumor cells is important for understanding the molecular basis 
of tumor recognition by T cells, and may lead to the devel- 
opment of new, more effective strategies for the treatment 
of patients with cancer. 
Through the use of molecular cloning strategies, five mela- 
noma antigens encoded by the MAGE-1 (9), MAGE-3 (10), 
tyrosinase (11, 12), gpl00 (13, 14), and MART-1/Melan-A 
(15, 16) genes have recently been identified. The proteins en- 
coded by MAGE-1 and MAGE-3 were shown to be recog- 
nized by CTL in association with HLA-A1 (9).  Genes en- 
coding  tyrosinase,  gpl00,  and  MART-1/Melan-A  were 
recently cloned and were recognized by HLA-A2-restricted 
CTL (11, 13-16)  while the tyrosinase antigen was also rec- 
ognized by HLA-A24-restricted CTL (12). Expression of three 
proteins, tyrosinase, gpl00, and MART-1/Melan-A, has been 
shown to be restricted to melanoma, normal melanocytes, 
and retina whereas MAGE-1 and MAGE-3 expression has been 
found in normal testis as well as in a variety of tumors (9-11, 
14, 15). Tyrosinase is a transmembrane glycoprotein expressed 
within melanosomes and has an enzymatic activity associated 
with the synthesis of melanin (17). Another enzyme associated 
with melanin synthesis is a tyrosinase-related protein (TRP- 
1), also called gp75. The gp75 protein was originally identified 
as an antigen recognized by serum IgG antibodies in a pa- 
tient with melanoma (18, 19). Like tyrosine and gpl00, gp75 
is abundantly expressed in human pigmented melanocytic cells 
and melanoma (20). 
The infusion of TIL586 plus IL-2 into the autologous pa- 
tient with melanoma resulted in the objective regression of 
mediastinal metastases (21). This lead us to attempt to iden- 
tify the tumor antigen recognized by TIL586. In the present 
study, we have used cDNA cloning strategy to isolate a gene 
encoding a shared human melanoma antigen recognized by 
TIL586 in association with HLA-A31. Analysis of the nucleo- 
tide sequence revealed that the cloned gene was almost iden- 
tical to that previously reported for gp75. 
Materials  and Methods 
Chemicals and Reagents.  The following chemicals and reagents 
were purchased from the sources indicated: KPMI 1640, AIM-V 
media, Lipofectamine, G418 (GIBCO BILL, Gaithersburg, MD); 
the eukaryotic expression vector pcDNA3 (Invitrogen, San Diego, 
CA); anti-HLA-A31 monoclonal antibody (One lambda, Canoga 
Park, CA);  anti-immunoglobulin  M antibody conjugated with 
fluorescein  isothiocyanate  (Vector  Laboratories,  Inc., Burlingame,  CA). 
CTLs and Cell Lines.  TIL586 were isolated from the tumor 
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medium containing IL-2 (6,000 IU/ml) (Chiron Corp., Emeryville, 
CA) for 32-60 d as previously described (21). TIL586 were pre- 
dominantly CD8 + T  cells.  TIL888 were grown under the same 
conditions  as described for TIL586. 
Melanoma cell lines 397mel, 526mel, 586mel, 624mel, 888mel, 
and 928mel and EBV transformed B cell line 586EBVB were estab- 
lished in this laboratory and cultured in RPMI 1640 medium con- 
taining 10% FCS. Normal cultured melanocytes derived from in- 
fant foreskin (NHEM530 purchased from Clonetics Corp.,  San 
Diego, CA; FM902 and FM906 provided by Dr. M. Herlyn, The 
Wistar Institute,  Philadelphia,  PA) were cultured in melanocyte 
growth medium (MGM; Clonetics Corp.).  The COS-7 cell line 
was provided by Dr. W. Leonard (National Institutes of Health, 
Bethesda, MD). 
GM-CSF  Secretion Assay.  Responder  cells  (1  x  l0  s)  and 
stimulator cells  (5  x  104-10  s) were mixed in 200/A  of AIM-V 
medium containing IL-2 (120 IU/ml) in a 96-well flat bottomed 
microplate. After incubation for 24 h,  100/11 of supernatant was 
collected and the amount of GM-CSF was measured in a standard 
ELISA assay (R+ D  System, Minneapolis, MN). Optical density 
was measured at 405 nm and the concentration of GM-CSF was 
calculated by comparison to GM-CSF standards in the same assay. 
Isolation of the HLA-A31  Gene.  Total mRNA was prepared from 
586mel cells using an RNA isolation kit (Stratagene,  La Jolla, CA). 
After the first-stranded cDNA was made using reverse transcrip- 
tase,  a PCR was carried out using a pair of primers (5UTA and 
3UTA) which was specific for the HLA-A allele and flanked the 
coding region (22). The PCR products were separated on 1.0% 
agarose gel and a 1.3-kb DNA fragment was isolated. Following 
BamHI and HindlII digestion, the DNA fragment was cloned into 
the  pBK vector (Stratagene).  The resultant  plasmid was called 
pWBK101.  The  HLA-A31  gene was then  sequenced  using  the 
dideoxynucleotide chain termination method (sequenase 2.0; United 
States Biomedical Corp., Cleveland, OH) to confirm that the se- 
quence corresponded  to the published DNA sequence. 
cDNA Expression Cloning and Screening.  A cDNA library pre- 
pared from 888mel was constructed as previously described (12) 
and used for screening. Plasmid DNAs were isolated from pools 
of bacteria containing 50-100 colonies.  DNA was transfected into 
COS-7 cells using Lipofectamine (GIBCO BRL). Briefly, 5  x  104 
cells were plated in 100/~1 of DMEM (Biofluids,  Inc., Rockville, 
MD) without  serum in a flat bottomed 96-well microplate. 200 
ng of DNA from each of the pools and 50 ng plasmid pWBK101 
containing the HLA-A31 gene were mixed with 2/A of lipofecta- 
mine in 100 #1 of DMEM for 15-45 min. The DNA/lipofecta- 
mine mixture was then added to the COS-7 cells and incubated 
overnight.  The following day,  the transfection medium was re- 
moved, cells were washed twice with DMEM medium. TIL586 
was added at a concentration of 10  s cells/well in AIM-V medium 
containing 120 IU/ml of IL-2. After 18-24-h incubation,  100/A 
of supernatant was evaluated for the release  of GM-CSF. 
Northern Blot Analysis.  Total IKNA was isolated by the guani- 
dine isothiocyanate/cesium chloride centrifugation method. Total 
RNA from human normal tissue was purchased from Clontech 
(Palo Alto, CA). 20 #g of total RNA was subjected to electropho- 
resis in a 1.2% agarose formaldehyde gel and transferred to a nylon 
membrane. A 2.2-kb ApaI DNA fragment of gp75 gene was la- 
beled by the random priming method.  Prehybridization and hy- 
bridization were performed according to the QuickHyb protocol 
(Stratagene). Membranes were washed twice with 2 x  SSC/0.1% 
SDS  at  room  temperature  for  15  rain  and  twice  with  0.1x 
SSC/0.1% SDS at 60~  for 30 min. The autoradiography was per- 
formed at  -70~ 
PCR Detection.for  gp75 Expression.  Reverse transcription was 
performed using 5 #g of total KNA with an oligo(dT) primer. 
cDNA corresponding to 100-500 ng of total KNA was amplified 
for 30 cycles by PCR using primers gpl and gpllB. 5 #l of PCR 
products  were  run  on  a  4%  nusieve  agarose gel  stained  with 
ethidium bromide. 
Results 
I, t  ation  HLA-A31  as    t tion  lem t  TILS86. 
Previous  studies  had  shown  that TIL586 lysed the autolo- 
gous  melanoma  cell  line  and  several allogeneic  melanoma 
targets derived from different patients which shared HLA-A31, 
-A29,  -Cw7, or -B44 (23).  However, TIL586 failed to lyse 
autologous nonmelanoma targets including EBV-transformed 
B cells. Results in Table I  indicated that an allogenic mela- 
noma matched at the HLA-A31 locus stimulated GM-CSF 
release from TIL586 while four of five melanoma cell lines 
not expressing HLA-A31 or an EBV-transformed B cell line 
expressing HLA-A31 failed to stimulate significant GM-CSF 
release. A recent study showed that the HLA-A29 allele was 
deleted in the 586mel line (24) and that TIL586 recognized 
an antigen  on the normal melanocyte cell line  NHEM680 
which shared HLA-A29, A31 and B44 (15). Therefore, these 
results  suggested  that  TIL586  recognized  a  melanocyte/ 
melanoma-specific antigen in the context of the HLA-A31. 
Interestingly, one melanoma cell line, 888mel (non-HLA-A31), 
did not express HLA-A31, but was found in this  (Table 1) 
and  other  experiments  to  stimulate  GM-CSF  release from 
TIL586. TIL888, previously shown to recognize tyrosinase as 
T ble  1.  Spec citr q Antig n  R r  by TILSS6 
Stimulators  GM-CSF release 
Cell lines  HLA-A31 expression  TIL586  TIL888* 
pg/ml 
397mel  -  31  13 
526mel  -  38  23 
586mel  +  >5,000  17 
624mel  -  25  12 
888mel  -  323  2,750 
928mel  -  15  14 
1353mel  +  926  15 
586EBVB  +  12  16 
TIL586 secreted GM-CSF when cultured with HLA-A31 melanoma cells. 
GM-CSF in the supernatant was measured after TIL586 and stimulator 
cells were coincubated for 24 h. GM-CSF secreted  by TILs alone without 
stimulators (<50 pg/ml) was subtracted. 586EBVB was a EBV trans- 
formed B cell line. All others were melanoma celI lines. 
" TIL888 is a HLA-A24-restricted CTL which recognizes the tyrosinase 
antigen in 888mel (12). 
800  Melanoma Differentiation Antigen gp75 a tumor antigen in an HLA-A24-restricted fashion and sharing 
the HLA-Cw7 class I allele with TIL586, failed to respond 
to 586mel. 
To confirm that HLA-A31 was the restriction element for 
TIL586, we isolated the HLA-A31 gene by KT-PCK and 
cloned it into pBK-CMV vector. The resultant plasmid was 
called pWBK10L We transfected pWBK101 into COS-7 cells 
and the human embryonic kidney cell line 293. The expres- 
sion of the HLA-A31 gene expressed on the cell surface was 
confirmed by FACS  |  analysis using anti-HLA-A31 antibody 
(data not shown). To test whether HLA-A31 was functional 
in presenting the melanoma antigen to TIL586, we trans- 
fected the HLA-A31 cDNA into the HLA-A31 negative mela- 
noma cell lines 397mel,  526mel, 624mel, and 888 mel and 
selected stable transfectants in G418-containing media. The 
expression of the HLA-A31 gene in the stable transfectants 
was evaluated by FACS  |  analysis.  Transfectants of 526mel, 
624mel, and 888mel expressing HLA-A31 significantly en- 
hanced  the  stimulation  of GM-CSF  release from TIL586 
whereas the HLA-A31 transfectant of 397mel failed to stimu- 
late increased GM-CSF release (Table 2). This failure of 397mel 
to stimulate cytokine release from TIL586 was attributed to 
the lack of expression of the antigen recognized by TIL586 
(Table 3).  FACS  |  analysis demonstrated  that  a  high  level 
of HLA-A31 expression was found on the surface of 397mel- 
A31 (data not shown). These results indicated that TIL586 
recognized a shared antigen expressed on a number of mela- 
nomas presented by the HLA-A31 MHC class  I molecule. 
Table  2.  Specific Secretion of GM-CSF by TIL586 Is 
HLA-A31 Restricted 
Stimulators 
Transfected  HLA-A31  GM-CSF 
Cell lines  gene  expression  secretion 
pg/ml 
None  None  -  <10 
397mel  None  -  47 
397mel  HLA-A31  +  99 
526mel  None  -  36 
526mel  HLA-A31  +  537 
624mel  None  -  39 
624mel  HLA-A31  +  1,120 
888mel  None  -  327 
888mel  HLA-A31  +  1,090 
586mel  None  +  >5,000 
586EBVB  None  +  29 
GM-CSF in the supernatant was measured after TILs were coincubated 
for 24 h with melanoma  cell lines with or without stably  transfected  HLA- 
A31. GM-CSF secreted  by TILs alone without stimulator (<50 pg/ml) 
was subtracted. 
Table 3.  Expression of gp75 in i~'fferent Cell Lines Tested 
Melanoma  Expression  Melanoma  Expression 
cell lines  of gp75  cell lines  of gp75 
397mei  -  1011mel  + 
526mel  +  1088mel  + 
537mel  +  1102mel  - 
553Bmel  +  C32  - 
586mel  +  RPMI7951  - 
624mel  +  WMl15  - 
677mel  +  HS695T  - 
679mel  -  A375  - 
697mel  +  SKnel  - 
729mel  -  586EBVB  - 
883mel  +  Melanocytes 
836mel  -  FM906  + 
888mel  +  FM902  + 
928mel  + 
938mel  -  Other tumor lines 
952mel  -  Daudi  - 
978mel  -  MDA231  - 
Expression of gp75 was tested by Northern blot analysis  with 10-20 #g 
of total KNA and probed with the 2.2-kb ApaI DNA fragment and by 
KT-PCK amplification  on total RNA with primers  gpl and gp11B. Daudi 
is a Burkitt's B cell line and MDA231 is a breast cancer cell line. 
Cloning of a eDNA Encoding a Melanoma Antigen Recog- 
nized by TIL586.  Since 888mel transfected with HLA-A31 
increased the stimulation of GM-CSF release from TIL586 
in comparison to non-transfected 888mel, 888mel seemed to 
express a shared antigen recognized by TIL586 and a cDNA 
library, which had previously been prepared with KNA from 
the 888mel cell line (12), was chosen for cloning this antigen. 
Each cDNA pool containing  50-100 cDNA clones was 
cotransfected with the pWBK101 containing the HLA-A31 
gene into COS-7 cells  using lipofectamine and transfected 
COS-7 cells were tested for the ability to stimulate GM-CSF 
release by TIL586. After the screening of 300 cDNA pools, 
we identified four positive cDNA pools; three cDNA pools 
consistently conferred the ability to stimulate secretion of GM- 
CSF  from  TIL586  twofold  higher  than  did  the  control 
plasmid, and one cDNA pool (pool 776) strongly stimulated 
GM-CSF release from TIL586. Individual cDNA clones were 
prepared from pool 776 and cotransfected into COS-7 cells 
with the HLA-A31 gene,  and  14 out of 100 clones tested 
were found to confer recognition by TIL586. Restriction anal- 
ysis demonstrated that the 14 positive clones appeared to con- 
tain a single 2.4-kd DNA insert which was called pcDNA776. 
A  representative experiment is  shown in Fig.  1.  The level 
of GM-CSF release stimulated by COS-7 cells transfected with 
pcDNA776 was comparable to that stimulated by the 586mel 
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Figure  1.  Northern blot analysis  of the gp75 expression. 20/xg  of total 
R.NAs from different  human tissues  was loaded. After  blotting, the mem- 
brane was probed  with a 2.2-kb ApaI DNA fragment of the gp75 gene. 
The detected  band for gp75 was marked. The 28S and 18S RNA were 
also  marked  and served  as a indication  of  similar amount of RNA being  used. 
cells, indicating that this may be a dominant antigen recog- 
nized by TIL586. 
The pcDNA776 insert was sequenced and found to be al- 
most identical to the cDNA sequence previously shown to 
encode melanocyte lineage  specific  protein,  gp75  (19,  25). 
Sequence comparison between pcDNA776 and gp75 cDNA 
from GenBank (25) revealed that pcDNA776 represented a 
partial cDNA clone which lacked the first 375 bp and had 
a different 3' end which appeared to be due to the usage of 
different polyadenylation sites. A full-length cDNA fragment 
(776FL) containing  the entire coding region  of gp75,  iso- 
lated by PCR using primers located in the 5' and 3' untrans- 
lated regions of the gene, was cloned into the expression vector 
pcDNA3. Transfection of either plasmid into COS-7 along 
with the HLA-A31 gene conferred the ability to stimulate 
comparable level of GM-CSF  secretion from TIL586  (data 
not  shown). 
The truncated cDNA776 clone lacked the authentic start 
codon and the leader peptide of the gp75 protein.  The full 
length  cDNA  contained  an  open  reading  frame  of 1,584 
nucleotides coding for a polypeptide of 527 amino acids with 
a molecular weight of 60 kD. No difference was found be- 
tween the amino  acid sequence encoded by pcDNA776FL 
insert and gp75, indicating  that TIL586 recognized a non- 
mutated peptide(s) derived from gp75. gp75, also called TRP-1 
has approximately 40-45%  amino acid sequence identity to 
tyrosinase (11,  12),  gp100  (14,  26,  27)  and TRP-2  (28). 
Expression ofGene  gp75.  Northern blot analyses were per- 
formed using cDNA776 gene as a probe to evaluate the ex- 
pression pattern  of pg75  in  different  tissues.  As  shown in 
Fig. 2, only retina was shown to be positive among the ten 
normal human  tissues tested.  This result was confirmed by 
RT-PCR analysis (data not shown). The expression pattern 
of gp75 in melanoma cell lines and other cell lines is listed 
in the Table 3.  12 of 26 melanoma cell lines were positive. 
The level of expression in the two melanocyte cell lines tested 
was about 10-fold lower than that found in the positive mela- 
Figure  2.  GM-CSF  release  by TIL586. GM-CSF  secretion  from  TIL586 
was significantly  increased  when co-incubated  with COS-7  cells  transfected 
with gp75 and HLA-A31 genes as described  in Materials and Methods. 
Control stimulatory cells included HLA-A31 586mel, 397mel, COS cell 
alone, and COS cells  transfected  with either HLA-A31  or the gp75 cDNA. 
TIL586 was coincubated  with stimulatory cells for 24 h and GM-CSF 
in the supernatant was measured. 
noma cell lines.  Two tumor lines tested, the Burkitt's B cell 
line Daudi and the breast cancer cell line MDA231, were nega- 
tive. Thus, like tyrosinase, gpl00 and MART-l,  the expres- 
sion pattern  of this gene appeared to be restricted to mela- 
noma,  normal  melanocyte cell lines,  and retina. 
Discussion 
The gp75 gene is the sixth gene that  has been identified 
as an antigen recognized by autologous CTL in patients with 
melanoma. MAGE-1 is expressed on a variety of tumor cells 
(melanoma,  lung cancer, breast cancer)  and testis, hut  not 
in other normal human tissues (9). Tyrosinase (11, 12), MART- 
1/Melan-A (15, 16), and gpl00 (13, 14) have been identified 
as melanoma antigens and they were expressed only in normal 
melanocytes, melanomas, and retina, but not in other normal 
tissues. 
Though sera from some melanoma patients contain anti- 
bodies against gp75, gp75 has not previously been identified 
as an  antigen  recognized by T  cells.  By the use of cDNA 
cloning, we have now identified the nonmutated gp75 as an 
antigen recognized by HLA-A31-restricted TIL586. This is 
further supported by the fact that TIL586 appeared to recog- 
nize the antigen on HLA-A31 § allogeneic melanocyte and 
melanoma cell lines. 
The gp75 protein is the most abundant  intracellular  gly- 
coprotein expressed in human pigmented melanocytic cells 
and melanoma cells (20) and is the homologue of the mouse 
b (brown) locus gene product (19, 29). The gene coding for 
gp75 has been mapped to chromosome 4 in the mouse (29) 
and to chromosome 9, 9q23 region in the human by in situ 
hybridization (30).  Genetic studies have shown that the mu- 
rine b  locus influences the biogenesis of melanosomes and 
controls the type of melanin produced (17). There was a di- 
rect correlation between melanin content and the expression 
of the four melanogenic  proteins,  tyrosinase,  gpl00,  gp75 
(TRP-1),  and TRP-2  (17).  The gp75 protein  has recently 
been demonstrated to have DHI-2-carboxylic acid oxidase ac- 
tivity,  which  is important  in  melanin  synthesis (31). 
802  Melanoma  Differentiation Antigen gp75 The presence of CTL and IgG antibodies against gp75 in 
some patients with metastatic melanoma indicates that au- 
toreactive T  cells and B cells existed and may be activated 
in vivo.  Since it is thought that high affinity lymphocytes 
are deleted in the induction of tolerance, only CTL with low 
or intermediate affinity are likely to exist against such an an- 
tigen (32).  The presence  of an immune response  to an an- 
tigen shared by tumor and normal cells raises important ques- 
tions about the nature and mechanism of immune responses 
to self antigens on growing tumor cells. The increased  ex- 
pression of gp75 in melanoma cells relative to that in mela- 
nocytes,  as demonstrated by Northern blot analysis, might 
be one important factor in the induction of a T cell response 
to the self antigen gp75. 
Shared differentiation antigens like those encoded by tyro- 
sinase, MART-1/Melan-A, gpl00,  and gp75  may serve as 
useful targets for immunotherapy. Local depigmentation in 
melanoma patients has been reported to correlate with pro- 
longed survival  (33, 34) and clinical response  to chemoim- 
munotherapy (35). The depigmentation may result from the 
destruction of melanocytes as a consequence of an immune 
response directed against these differentiation antigens. After 
receiving the infusion of 2.3  x  1011 TIL586 cells plus IL-2, 
patient 586 experienced partial regression  (<50% reduction) 
of all measurable lesions,  including two cervical cutaneous 
metastases, anterior mediastinal mass and a mass in the right 
lung. There were no adverse effects related to melanocyte de- 
struction. These results suggest that CTLs directed against 
shared differentiation antigens may be useful for the immuno- 
therapy of patients with melanoma. Nevertheless,  it will be 
of  importance to determine any adverse side effects on normal 
tissue upon immunization with these melanocyte lineage spe- 
cific antigens including gp75, gpl00, MART-l, and tyrosinase. 
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